Concentrations of omentin and vaspin versus insulin resistance in obese individuals

Biomedicine and Pharmacotherapy

Volumn 83, Issue , 2016, Pages 542-547

  Sperling, Marcelina ^a   Grzelak, Teresa ^a   Pelczyńska, Marta ^a   Jasinska, Paula ^a   Bogdanski, Pawel ^a   Pupek Musialik, Danuta ^a   Czyzewska, Krystyna ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Insulin resistance; Obesity; Omentin; Vaspin

Indexed keywords

ADIPOCYTOKINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; OMENTIN; UNCLASSIFIED DRUG; VASPIN; CYTOKINE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; ITLN1 PROTEIN, HUMAN; LECTIN; SERINE PROTEINASE INHIBITOR; SERPINA12 PROTEIN, HUMAN;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FAT MASS; FEMALE; GLUCOSE TOLERANCE; HIP CIRCUMFERENCE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULINEMIA; LEAN BODY WEIGHT; LIPOPROTEIN BLOOD LEVEL; MALE; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; ANTHROPOMETRY; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED; RECEIVER OPERATING CHARACTERISTIC;

ADULT; ANTHROPOMETRY; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; GPI-LINKED PROTEINS; HUMANS; INSULIN RESISTANCE; LECTINS; MALE; MIDDLE AGED; OBESITY; ROC CURVE; SERPINS;

EID: 84978701836     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.07.012     Document Type: Article

References (34)

1. [1] Bays, H.E., Adiposopathy is “sick fat” a cardiovascular disease?. J. Am. Coll. Cardiol. 57 (2011), 2461–2473 http://www.sciencedirect.com/science/article/pii/S073510971101312X.
2. [2] Samuel, V.T., Shulman, G.I., Mechanisms for insulin resistance: common threads and missing. Cell 5 (2012), 852–871 http://www.sciencedirect.com/science/article/pii/S0092867412002176.
3. [3] Lanthier, N., Leclercq, I.A., Adipose tissues as endocrine target organs. Best Pract. Res. Clin. Gastroenterol. 28 (2014), 545–558 http://www.sciencedirect.com/science/article/pii/S1521691814000808.
4. [4] Koleva, D., Orbetzova, M.M., Atanassova, P.K., Adipose tissue hormones and appetite and body weight regulators in insulin resistance. Folia Med. (Plovdiv) 55:1 (2013), 25–32 http://www.ncbi.nlm.nih.gov/pubmed/23905484.
5. [5] Blüher, M., Adipokines—removing road blocks to obesity and diabetes therapy. Mol. Metab. 3:3 (2014), 230–240 http://www.sciencedirect.com/science/article/pii/S2212877814000106.
6. [6] Definition diagnosis of diabetes mellitus intermediate hyperglycemia. Report of a WHO/IDF Consultation, 2006, WHO Document Production Services, Geneva https://www.idf.org/webdata/docs/WHO_IDF_definition_diagnosis_of_diabetes.pdf.
7. [7] Physical status: the use and interpretation of anthropometry, Report of a WHO Expert Committee. World Health Organization technical report series, 854, 1–452. http://apps.who.int/iris/bitstream/10665/37003/1/WHO_TRS_854.pdf (1995).
8. [8] Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., Galderisi, M., Grobbee, D.E., Jaarsma, T., Kirchhof, P., Kjeldsen, S.E., Laurent, S., Manolis, A.J., Nilsson, P.M., Ruilope, L.M., Schmieder, R.E., Sirnes, P.A., Sleight, P., Viigimaa, M., Waeber, B., Zannad, F., Task Force Members 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 31:7 (2013), 1281–1357 http://www.esh2013.org/wordpress/wp-content/uploads/2013/06/ESC-ESH-Guidelines-2013.pdf.
9. [9] Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C., Homeostasis model assessment insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:7 (1985), 412–419 http://www.ncbi.nlm.nih.gov/pubmed/3899825.
10. [10] Lorenzo, C., Haffner, S.M., Stancáková, A., et al. Relation of direct and surrogate measures of insulin resistance to cardiovascular risk factors in nondiabetic finish offspring of type 2 diabetic individuals. J. Clin. Endocrinol. Metab. 95:11 (2010), 5082–5090 http://press.endocrine.org/doi/10.1210/jc.2010-1144?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed.
11. [11] Belfiore, F., Iannello, S., Volpicelli, G., Insulin sensitivity indices calculated from basal and OGTT-induced insulin, glucose, and FFA levels. Mol. Genet. Metab. 2 (1998), 134–141 http://www.sciencedirect.com/science/article/pii/S1096719297926585.
12. [12] Petta, S., Di Marco, V., Di Stefano, R., et al. TyG index: HOMA score and viral load in patients with chronic hepatitis C due to genotype 1. J. Viral Hepat. 18:7 (2011), 372–380 http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2893.2011.01439.x/full.
13. [13] Liu, P.J., Ma, F., Lou, H.P., et al. Visceral Adiposity Index is associated with pre-diabetes and type 2 diabetes mellitus in Chinese adults aged 20–50. Ann. Nutr. Metab. 68 (2016), 235–243 http://www.karger.com/Article/FullText/446121.
14. [14] Hosmer, D., Lemeshow, S., Applied Logistic Regression. 2nd edition, 2013, John Wiley & Sons Inc., New York http://eu.wiley.com/WileyCDA/WileyTitle/productCd-0470582472. html.
15. [15] Yamawaki, H., Vascular effects of novel adipocytokines: focus on vascular contractility and inflammatory responses. Biol. Pharm. Bull. 34 (2011), 307–310 https://www.jstage.jst.go.jp/article/bpb/34/3/34_3_307/_article.
16. [16] Moreno-Navarrete, J., Catalán, V., Ortega, F., Gómez-Ambrosi, J., Ricart, W., Frühbeck, G., Fernández-Real, J.M., Circulating omentin concentration increases after weight loss. Nutr. Metab., 7, 2010, 27, 10.1186/1743-7075-7-27 http://www.nutritionandmetabolism.com/content/7/1/27.
17. [17] Zhou, J.Y., Chan, L., Zhou, S.W., Omentin linking metabolic syndrome and cardiovascular disease. Curr. Vasc. Pharmacol. 12:1 (2014), 136–143 http://www.ingentaconnect.com/content/ben/cvp/2014/00000012/00000001/art00017?crawler=true.
18. [18] von Loeffelholz, C., Möhlig, M., Arafat, A.M., Isken, F., Spranger, J., Mai, K., Randeva, H.S., Pfeiffer, A.F., Weickert, M.O., Circulating vaspin is unrelated to insulin sensitivity in a cohort of nondiabetic humans. Eur. J. Endocrinol. 162:3 (2010), 507–513 http://www.eje-online.org/content/162/3/507.long.
19. [19] Li, X.P., Zeng, S., Wang, M., Wu, X.P., Liao, E.Y., Relationships between serum omentin-1, body fat mass and bone mineral density in healthy Chinese male adults in Changsha area. J. Endocrinol. Invest. 37:10 (2014), 991–1000.
20. [20] El-Mesallamy, H.O., Kassem, D.H., El-Demerdash, E., Amin, A.I., Vaspin and visfatin/nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus. Metabolism 60:1 (2011), 63–70 http://www.sciencedirect.com/science/article/pii/S0026049510001277.
21. [21] Gulcelik, N.E., Karakaya, J., Gedik, A., Usman, A., Gurlek, A., Serum vaspin levels in type 2 diabetic women in relation to microvascular complications. Eur. J. Endocrinol. 160:1 (2009), 65–70 http://www.eje-online.org/content/160/1/65.long.
22. [22] Li, Q., Chen, R., Moriya, J., A novel adipocytokine, visceral adipose tissue-derived serine protease inhibitor (vaspin), and obesity. J. Int. Med. Res. 36 (2008), 625–629 http://imr.sagepub.com/content/36/4/625.long.
23. [23] Klöting, N., Kovacs, P., Kern, M., et al. Central vaspin administration acutely reduces food intake and has sustained blood glucose-lowering effects. Diabetologia 54 (2011), 1819–1823 http://link.springer.com/article/10.1007%2Fs00125-011-2137-1.
24. [24] de Souza Batista, C., Yang, R.Z., Lee, M.J., et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 56 (2007), 1655–1661 http://diabetes.diabetesjournals.org/content/56/6/1655.long.
25. [25] Cinar, N., Gurlek, A., Association between novel adipocytokines adiponectin, vaspin, visfatin and thyroid: an experimental and clinical update. Endocr. Connect. 2:4 (2013), R30–R38 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3847914/.
26. [26] Jian, W., Peng, W., Xiao, S., Li, H., Jin, J., Qin, L., Dong, Y., Su, Q., Role of serum vaspin in progression of type 2 diabetes: a 2-year cohort study. PLoS One, 9(4), 2014, e94763 (10.1371. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3986225/).
27. [27] Bergmann, K., Sypniewska, G., Diabetes as a complication of adipose tissue dysfunction Is there a role for potential new biomarkers?. Clin. Chem. Lab. Med. 51 (2013), 177–185.
28. [28] Sabooria, S., Hosseinzadeh-Attara, M.J., Yousefi, E., Hosseinic, M., Mirzaeia Ahmadivanda, K.Z., The comparison of serum vaspin and visfatin concentrations in obese and normal weight women. Diabetes Metab. Syndr., 2013, 10.1016/j.dsx.2013.10.009 http://www.sciencedirect.com/science/article/pii/S1871402113000994.
29. [29] Körner, A., Neef, M., Friebe, D., Vaspin is related to gender, puberty and deteriorating insulin sensitivity in children. Int. J. Obes. 35 (2011), 578–586 http://www.nature.com/ijo/journal/v35/n4/full/ijo2010196a.html.
30. [30] Esaki, E., Adachi, H., Hirai, Y., Yamagishi, S., Kakuma, T., Enomoto, M., Fukami, A., Kumagai, E., Ohbu, K., Obuchi, A., Yoshimura, A., Nakamura, S., Nohara, Y., Fujiyama, T., Fukumoto, Y., Imaizumi, T., Serum vaspin levels are positively associated with carotid atherosclerosis in a general population. Atherosclerosis 233:1 (2014), 248–252 http://www.sciencedirect.com/science/article/pii/S0021915013007934.
31. [31] Jaikanth, C., Gurumurthy, P., Cherian, K.M., Indhumathi, T., Emergence of omentin as a pleiotropic adipocytokine. Exp. Clin. Endocrinol. Diabetes 121:7 (2013), 377–383 https://www.thieme-connect.com/products/ejournals/html/10.1055/s-0033-1345123.
32. [32] Herder, C., Ouwens, D.M., Carstensen, M., Kowall, B., Huth, C., Meisinger, C., Rathmann, W., Roden, M., Thorand, B., Adiponectin may mediate the association between omentin, circulating lipids and insulin sensitivity: results from the KORA F4 study. Eur. J. Endocrinol. 172:4 (2015), 423–432 http://www.eje-online.org/lookup/pmid?view=long&pmid=25733068.
33. [33] Katsi, V., Vamvakou, G., Lekakis, J., Tousoulis, D., Stefanadis, C., Makris, T., Kallikazaros, I., Omentin, fat and heart: classical music with new instruments. Heart Lung Circ. 23:9 (2014), 802–806 http://www.sciencedirect.com/science/article/pii/S1443950614001310.
34. [34] Makni, E., Moalla, W., Lac, G., Aouichaoui, C., Cannon, D., Elloumi, M., Tabka, Z., The Homeostasis Model Assessment-adiponectin (HOMA-AD) is the most sensitive predictor of insulin resistance in obese children. Ann. Endocrinol. 73:1 (2012), 26–33.